Udskriv Udskriv
Switch language
Hvidovre Hospital - en del af Københavns Universitetshospital

Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Flu Vaccine and Mortality in Hypertension: A Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Pradeesh Sivapalan
  • Charlotte Suppli Ulrik
  • Therese Sophie Lappere
  • Josefin Viktoria Eklöf
  • Saher Burhan Shaker
  • Uffe Christian Steinholtz Bødtger
  • Andrea Browatzki
  • Christian Niels Meyer
  • Ulla Møller Weinreich
  • Christian B Laursen
  • Tor Biering-Sørensen
  • Filip Krag Knop
  • Jens D Lundgren
  • Jens-Ulrik Stæhr Jensen
Vis graf over relationer

BACKGROUND: There is an urgent need for treatments that can shorten hospitalization and lower the risk of secondary infection and death in patients with corona disease. The ProPac-COVID trial evaluates whether combination therapy with macrolide azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy, and pre-emptive treatment of supra-infections can shorten hospitalization duration and reduce the risk of non-invasive ventilation, treatment in the intensive care unit, and death in patients with acute hospital admission and a positive test for 2019-nCoV and symptoms of COVID-19 disease.

METHODS: The ProPAC-COVID is a multi-center, randomized, placebo-controlled, double-blinded clinical trial. The primary outcome is number of days spent alive and out of hospital within 14 days from randomization. Randomization will be in blocks of unknown size, and the final allocation will be stratified for age, site of recruitment, and whether the patient has any chronic lung diseases. Data is analyzed using intention-to-treat (ITT) principles, and main analyses will also be subject to modified ITT analysis and per protocol analysis.

DISCUSSION: This paper describes the detailed statistical analysis plan for the evaluation of primary and secondary endpoints of the ProPAC-COVID study. Enrolment of patients to the ProPAC-COVID study is still ongoing. The purpose of this paper is to provide primary publication of study results to prevent selective reporting of outcomes, data-driven analysis, and to increase transparency.

TRIAL REGISTRATION: NCT04322396 . Registered on 26 March 2020.

Udgave nummer1
Sider (fra-til)867
Antal sider9
StatusUdgivet - 20 okt. 2020

ID: 61074133